Back
Delegates Premium Access

Prevalence and clinical relevance of familial hypercholesterolemia-causing mutations in Germany

Session: Dyslipidaemia management in 2025: status quo and best practice (2)
Topic: Cardiovascular Risk Assessment
Speaker: Doctor N. Arnold (Hamburg, DE)
Event: ESC Preventive Cardiology 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Natalie Arnold

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)
0 follower

5 more presentations in this session

Gender differences in the management of dyslipidemia in Switzerland

Speaker: Doctor R. de La Harpe (Lausanne, CH)

Access
Abstract
Slides
Like
Thumbnail

More musculoskeletal disorders and poor pain management in patients with familial hypercholesterolemia and self-perceived side effects to cholesterol-lowering treatment

Speaker: Ms A. Uduma (Oslo, NO)

Access
Abstract
Slides
Like
Thumbnail

Monetary costs and LDL-C reduction from upfront combination lipid-lowering therapy with ezetimibe in an irish ACS cohort

Speaker: Doctor D. Butler (Galway, IE)

Access
Abstract
Slides
Like
Thumbnail

Evaluation of LDL levels and lipid optimisation in high cardiovascular risk patients in nurse-led clinics in Ireland: a cross-sectional study

Speaker: Mrs M. Brennan (Waterford, IE)

Access
Abstract
Slides
Like
Thumbnail

Comparative effectiveness of novel anti-hyperlipidemic drugs in adults with hyperlipidemia: a systematic review and bayesian network meta-analysis

Speaker: Doctor V. Lanari (Milan, IT)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Dyslipidaemia management in 2025: status quo and best practice (2)

Speakers: Doctor N. Arnold, Doctor R. de La Harpe, Ms A. Uduma, Doctor D. Butler, Mrs M. Brennan...
Access
Like
Thumbnail

About the event

Image

ESC Preventive Cardiology 2025

3 April - 5 April 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources